Bioactive compounds derived from marine source: a potential immunotherapy treatment.

Area of Science:

• Marine natural products chemistry
• Immunotherapy
• Computational drug discovery

Background:

• Immunotherapy harnesses checkpoint inhibitors to block interactions like programmed cell death receptor-1 (PD-1) and programmed cell death receptor ligand-1 (PD-L1), crucial for regulating immune responses.
• The marine environment is a rich, yet underexplored, source of novel small molecules with therapeutic potential.

Purpose of the Study:

• To investigate the potential of algae-derived small molecules as inhibitors of PD-L1.
• To identify specific compounds with high binding affinity to PD-L1 using computational methods.

Main Methods:

• Screening of 19 algae-derived small molecules against PD-L1 using molecular docking.
• Assessment of Absorption, Distribution, Metabolism, and Excretion (ADME) properties.
• Molecular Dynamics Simulations (MDS) to evaluate complex stability.

Main Results:

• Six compounds exhibited significant binding energies, ranging from -11.1 to -9.1 kcal/mol.
• Fucoxanthinol demonstrated the strongest binding affinity (-11.1 kcal/mol) with key hydrogen bonds to PD-L1.
• MDS confirmed the stable interaction between the identified ligands and the PD-L1 protein.

Conclusions:

• Algae-derived compounds, particularly fucoxanthinol, show promise as novel PD-L1 inhibitors.
• These findings support the development of marine natural products for cancer immunotherapy.